Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Do Not Disrespect NAD: FTC Stresses Compliance With Self-Regulatory Groups

This article was originally published in The Tan Sheet

Executive Summary

The decision by the maker of Sunpill sunscreen tablets not to comply with the National Advertising Division's recommendations to change its advertising claims is an uncommon response that will get the Federal Trade Commission's attention, Lesley Fair, senior attorney in FTC's Division of Consumer Education, says

You may also be interested in...



Dietary Supplement Ads Most Common Among Cases NAD Picks To Review

Dietary supplement advertising accounted for "the largest share" of the cases the National Advertising Division of the Council of Better Business Bureaus identified through active monitoring in the past five years, says NAD Associate Director David Mallen

Dietary Supplement Ads Most Common Among Cases NAD Picks To Review

Dietary supplement advertising accounted for "the largest share" of the cases the National Advertising Division of the Council of Better Business Bureaus identified through active monitoring in the past five years, says NAD Associate Director David Mallen

Dietary Supplement Ads Most Common Among Cases NAD Picks To Review

Dietary supplement advertising accounted for "the largest share" of the cases the National Advertising Division of the Council of Better Business Bureaus identified through active monitoring in the past five years, says NAD Associate Director David Mallen

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel